Clinical trials: Influenza Vaccines
Safety Issues
Reactogenicity, Safety and Immunogenicity of an Universal Influenza Vaccine Uniflu
This is a single-site, randomized, double-blind, placebo-controlled study of Uniflu in fifty four (54) volunteers 18-60 years of age with a dose escalation.
- Trial name
- NCT03789539
- Testing
- LD Universal Influenza Vaccine Uniflu, HD Universal Influenza Vaccine Uniflu
- Where
- Russia
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- VA Pharma Limited Liability Company
Influenza in Human
Comparison of Laser Assisted Epidermal to Intradermal Administration of Seasonal Influenza Vaccine
It is the aim of the present study to compare the immunogenicity induced by a laser-assisted epidermally administered seasonal influenza vaccine to an intradermally administered seasonal influenza vaccine.
- Trial name
- NCT02988739
- Testing
- seasonal influenza vaccine, fractional Er:Yag laser
- Where
- Austria
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Pantec Biosolutions AG
Virus Diseases
Study to Evaluate the Efficacy and Safety of Danirixin Co-administered With Oseltamivir in the Treatment of Adults Hospitalized With Influenza
Danirixin (DNX) is a novel, selective, and reversible antagonist of the C-X-C chemokine receptor (CXCR) 2 and has been shown to decrease neutrophil transmigration and activation to areas of inflammation.
- Trial name
- NCT02927431
- Testing
- Danirixin 15 mg FBE, Danirixin 50 mg FBE, Oseltamivir 75 mg
- Where
- 8 sites in United States, Romania and 2 more
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Influenza
Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young Children
A study to assess whether the Northern Hemisphere 2009/2010 season influenza vaccine Inflexal V is as immunogenic as a locally sourced competitor vaccine in young children.
- Trial name
- NCT01310400
- Testing
- Inflexal V, Agrippal
- Where
- China
- Volunteers
- 1,356 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1010 in Healthy Adults
The main purpose of the study is to evaluate the safety, reactogenicity, and the humoral immunogenicity of mRNA-1010 and comparator influenza vaccines against homologous influenza A and B strains at Day 29.
- Trial name
- NCT05606965
- Testing
- mRNA-1010, Egg-based Quadrivalent Influenza Vaccine, Adjuvanted Quadrivalent Influenza Vaccine
- Where
- United States
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Influenza
Clinical Study to Evaluate Safety, Immunogenicity of Investigational Flu Vaccine Compared to an Approved Flu Vaccine (QIV) in Children Previously Vaccinated in Trial V118_05
Safety, Immunogenicity of an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine Compared to Non-Adjuvanted Comparator Influenza Vaccine in Children Previously Vaccinated in Trial V118_05
- Trial name
- NCT02255409
- Testing
- Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV), non-adjuvanted Quadrivalent Influenza Vaccine (QIV)
- Where
- 28 sites in United States, Finland
- Volunteers
- 607 people, healthy volunteers welcome
- Sponsor
- Seqirus
Influenza
A Study for Evaluation of GSK Biologicals' Pandemic Influenza Vaccine.
This observer-blind study is designed to show the immunological non-inferiority of Thiomersal-free-processed pandemic influenza vaccine as compared to the Thiomersal-containing-processed pandemic influenza vaccine.
- Trial name
- NCT00812981
- Testing
- GSK1562902A
- Where
- Taiwan
- Volunteers
- 320 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza A
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03999554
- Testing
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine
- Where
- 4 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Influenza
Study to Assess the Effect of Multistrain Probiotic on the Immune Response to the Influenza Vaccination
A randomized, triple-blinded, placebo-controlled, parallel group study, to assess the effect of multistrain probiotic on the immune response to the Influenza vaccination
- Trial name
- LUPIN (NCT06103994)
- Testing
- Multistrain probiotic
- Where
- Greece
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- The Archer-Daniels-Midland Company
GCP
Evaluate the Safety and Efficacy of Quadrivalent Influenza in Real-world Situations.
To evaluate the inter-batch consistency (CI) of quadrivalent influenza vaccine (split virion) among healthy people aged 18-59 years； Secondly, to evaluate the safety and immunogenicity of quadrivalent influenza vaccine (split…
- Trial name
- NCT06334510
- Testing
- One dose of quadrivalent influenza virus split vaccine was administered
- Where
- China
- Volunteers
- 4,900 people, healthy volunteers welcome
- Sponsor
- Hualan Biological Bacterin Co. Ltd.
Influenza
Safety and Immunogenicity of Quadrivalent Recombinant Influenza Vaccine Formulations Containing Different H3 Hemagglutinin Antigens in Healthy Adult Subjects 18 to 30 Years of Age
The primary objectives of the study are: To describe the safety profile of the different quadrivalent recombinant influenza vaccine (RIV) formulations.
- Trial name
- FBP00001 (NCT04144179)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 2, Quadrivalent RIV with H3 strain 3
- Where
- 3 sites in United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza Season
A study to evaluate the humoral immune response 3 weeks after vaccination with Inflexal V according to the CHMP criteria in elderly subjects for the 2011/2012 WHO recommended vaccine strains, to evaluate immunogenicity parameters…
- Trial name
- NCT01457027
- Testing
- Inflexal V
- Where
- Italy
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Crucell Holland BV
Influenza
Study of Sanofi Pasteur's Intradermal Influenza Vaccine (IDflu™) in Adults and Elderly in Korea
This study is designed to assess the immunogenicity and safety of the 2010-2011 NH season formulation of intradermal (ID) influenza vaccine as part of a post registration commitment.
- Trial name
- NCT01215669
- Testing
- IDflu™: Split virion inactivated influenza vaccine, Vaxigrip®: Split virion inactivated influenza vaccine
- Where
- 2 sites in South Korea
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Phase 1 Study of ATR-002
This was a combination of a single ascending dose (SAD) study to evaluate the safety, tolerability, and PK of 3 oral doses of a MEK inhibitor and a multiple ascending dose (MAD) study of 3 oral doses of a MEK inhibitor.
- Trial name
- NCT04385420
- Testing
- ATR-002 MEK Inhibitor
- Where
- Belgium
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Atriva Therapeutics GmbH
Influenza
Phase 1b Influenza Vaccine Study in Healthy Subjects
The purpose of this study is to see whether a single vaccination (injection) with the investigational influenza vaccine is safe in healthy subjects.
- Trial name
- NCT01181336
- Testing
- Influenza vaccine (FLU-v), FLU-v Control
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- PepTcell Limited
Healthy
Trial to Determine the Safety and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live, Cold-Adapted (CAIV-T) in Healthy Children
The purpose of this study is to determine the efficacy of CAIV-T in a diverse Asian population aged from 6 months to less than 36 months, in tropical and temperate climates, against culture-confirmed influenza illness.
- Trial name
- NCT00192244
- Testing
- CAIV-T, Liquid
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza
Comparative Clinical Trial of Efficacy and Safety of Ergoferon Versus Oseltamivir in Treatment of Influenza
The purpose of this study is: to assess the efficacy of Ergoferon in treatment of influenza; to assess the safety of Ergoferon in treatment of influenza; to compare the efficacy of Ergoferon and Oseltamivir for treatment of…
- Trial name
- NCT01850446
- Testing
- Ergoferon, Oseltamivir
- Where
- 7 sites in Russia
- Volunteers
- 184 people
- Sponsor
- Materia Medica Holding
Influenza
Safety and Immunogenicity of PanBlok Influenza Vaccine in Healthy Adults
The purpose of this study is to investigate the safety and immunogenicity of a recombinant hemagglutinin (rHA) influenza vaccine derived from A/Indonesia/05/2005 (H5N1) administered at 4 dose levels in adjuvanted (GLA-SE) rHA…
- Trial name
- NCT01147068
- Testing
- 0.5mL Intramuscular Injection
- Where
- 4 sites in United States
- Volunteers
- 392 people, healthy volunteers welcome
- Sponsor
- Protein Sciences Corporation
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine, Fluarix®/Influsplit SSW® (2013/2014 Season), in Adults 18 Years of Age and Older
The purpose of this study is to assess, in adults 18 years of age and above, the immunogenicity and reactogenicity of the seasonal influenza vaccine, Fluarix/Influsplit SSW 2013/2014, containing the three vaccine influenza…
- Trial name
- NCT01884519
- Testing
- Fluarix/Influsplit SSW® (2013-2014 season)
- Where
- 4 sites in Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Relenza® Sentinel Site Monitoring Program in Japan
To collect background information of patients receiving a prescription for Relenza® and study risk factors etc. for adverse drug reactions collected through spontaneous reporting.
- Trial name
- SSMP (NCT01199744)
- Testing
- zanamivir
- Volunteers
- 1,575 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.